Welcome to our dedicated page for CLRBW news (Ticker: CLRBW), a resource for investors and traders seeking the latest updates and insights on CLRBW stock.
Cellectar Biosciences, Inc. (CLRBW) is a clinical-stage biopharmaceutical company pioneering targeted cancer treatments through its proprietary Phospholipid Drug Conjugate™ (PDC™) platform. This page provides investors and healthcare professionals with timely updates on clinical developments, regulatory milestones, and strategic partnerships.
Access consolidated, verified information about Cellectar’s radiopharmaceutical pipeline including iopofosine I-131 for hematologic cancers and actinium-based therapies for solid tumors. Our news collection covers essential updates including trial results, FDA designations, manufacturing collaborations, and financial disclosures.
Key content areas include progress reports on late-stage clinical programs, analyses of therapeutic mechanisms, and coverage of scientific presentations. All materials maintain strict compliance with financial disclosure regulations while prioritizing accessibility for both specialist and general audiences.
Bookmark this page for streamlined tracking of Cellectar’s advancements in precision oncology. For comprehensive monitoring of CLRBW developments, consider subscribing to our news alerts or consulting additional regulatory filings.
Cellectar Biosciences (NASDAQ:CLRB) has partnered with Evestia Clinical to conduct a Phase 1b clinical trial for CLR 125, an iodine-125 Auger-emitting drug candidate targeting triple-negative breast cancer (TNBC). The trial is set to begin in Q4 2025 at Mayo Clinic, with Dr. Pooja Advani serving as lead investigator.
Evestia Clinical, recently merged with Atlantic Research Group (ARG), will provide comprehensive CRO services, leveraging their experience from over 300 oncology studies. CLR 125 is being developed to treat various solid tumors, including triple negative breast, lung, and colorectal cancers.
Cellectar Biosciences (NASDAQ:CLRB) has entered into a supply agreement with ITM Isotope Technologies Munich SE for Actinium-225 (Ac-225), a crucial isotope for targeted cancer therapies. The agreement will support the clinical development of Cellectar's CLR 121225, a Phase 1-ready compound for treating solid tumors, particularly pancreatic cancer.
The partnership addresses the critical challenge of Ac-225 scarcity in radiopharmaceutical development. ITM, through its joint venture Actineer with Canadian Nuclear Laboratories, will provide Cellectar with medical-grade Ac-225. CLR 121225 has shown promising anti-tumor effects in preclinical studies, utilizing Cellectar's proprietary phospholipid ether (PLE) delivery platform for selective cancer cell targeting.
Cellectar Biosciences (NASDAQ: CLRB) announced its participation in the Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit on September 11, 2025. The company will discuss several key developments:
The company awaits EMA's decision in late Q3/early Q4 2025 regarding a potential Conditional Marketing Authorization submission for iopofosine I 131 to treat Waldenstrom Macroglobulinemia (WM). Additionally, Cellectar plans to pursue FDA accelerated approval for the same treatment, supported by positive Phase 2b CLOVER WaM trial results.
Cellectar also plans to initiate a Phase 1b trial of CLR 125, their Auger-emitting radiopharmaceutical, for treating triple-negative breast cancer in Q4 2025. The company has secured long-term multi-isotope supply agreements for iodine-125 and actinium-225.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company, announced its participation in multiple medical meetings and industry conferences throughout September 2025. Chief Operating Officer Jarrod Longcor will present at five major events, including the ADC and Novel Conjugates Summit, BioProcess International, and specialized conferences focused on cancer research.
The company will showcase its proprietary Phospholipid Drug Conjugate™ (PDC) platform and discuss its product pipeline, including iopofosine I 131 and other radiopharmaceutical candidates. Notable presentations will cover pediatric brain tumors, pancreatic cancer research, and radiopharmaceutical manufacturing challenges.
Cellectar Biosciences (NASDAQ: CLRB) announced the acceptance of an abstract for poster presentation at the AACR Special Conference on Pancreatic Cancer Research in Boston from September 28-October 1, 2025. The presentation will showcase preclinical data for CLR 121225, the company's novel actinium-based radio conjugate alpha-emitter designed to treat hypoxic pancreatic ductal adenocarcinoma.
Chief Operating Officer Jarrod Longcor will present the poster titled "Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225" on September 30. The company reports that preclinical studies have demonstrated promising activity, biodistribution, and uptake across multiple solid tumor animal models, with IND-enabling activities currently in progress.
Cellectar Biosciences (NASDAQ: CLRB) announced that it will present interim data from its CLOVER-2 Phase 1b clinical trial at the upcoming AACR Special Conference on Pediatric Cancer in Boston. The presentation will focus on the study of iopofosine I 131 in treating inoperable relapsed or refractory pediatric high-grade glioma (r/r pHGG).
The company's abstract has been selected for an oral presentation in a plenary session on September 26, 2025, followed by a 55-minute panel discussion. Chief Operating Officer Jarrod Longcor will present the interim findings, which the company reports as encouraging, suggesting potential clinical benefits for patients with limited treatment options.
Cellectar Biosciences (NASDAQ:CLRB) reported Q2 2025 financial results and provided significant updates on its radiopharmaceutical pipeline. The company plans to pursue an FDA NDA submission for iopofosine I 131 to treat Waldenstrom Macroglobulinemia (WM) under accelerated approval, subject to funding and confirmatory trial initiation. The drug received FDA Breakthrough Therapy Designation for WM treatment.
Key financial metrics include cash position of $11.0 million as of June 30, 2025, with an additional $5.8 million raised in July 2025. R&D expenses decreased to $2.4 million from $7.3 million year-over-year, while Q2 net loss was $5.4 million. The company expects current funding to support operations into Q2 2026.
In pediatric high-grade glioma trials, patients receiving minimum dosing showed 5.4 months progression-free survival and 8.6 months overall survival. The company plans to advance CLR 125 into Phase 1 TNBC trials by Q4 2025.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company specializing in cancer treatment drug development, has scheduled its second quarter 2025 financial results announcement and corporate update for August 14, 2025, at 8:30 AM ET.
The company will host a conference call accessible via toll-free number 1-800-717-1738 (Conference ID: 94699) and webcast. A replay of the presentation will be made available in the Events section of Cellectar's Investor Relations website.
Cellectar Biosciences (NASDAQ:CLRB) has successfully closed its previously announced underwritten public offering, raising $6.9 million in gross proceeds. The offering consisted of 1,045,000 Class A Units priced at $5.00 each and 335,000 Class B Units at $4.99999 each, including the full exercise of the over-allotment option.
Each Class A Unit includes one common stock share and one common warrant, while Class B Units contain one pre-funded warrant and one common warrant. The Common Warrants have a $5.25 exercise price and a 5-year term. The company plans to use proceeds for general corporate purposes and to initiate a Phase 1b clinical study of CLR 121125 in triple-negative breast cancer.
Cellectar Biosciences (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on cancer drug development, has announced the pricing of an underwritten public offering to raise approximately $6 million in gross proceeds.
The offering consists of 865,000 Class A Units at $5.00 per unit (including one common stock share and one common warrant) and 335,000 Class B Units at $4.99999 per unit (including one pre-funded warrant and one common warrant). The common warrants will have an exercise price of $5.25 per share with a five-year term.
The company plans to use the proceeds for general corporate purposes, working capital, and to initiate a Phase 1b clinical study of CLR 121125 (CLR 125) in triple-negative breast cancer. Ladenburg Thalmann & Co. Inc. is serving as the sole bookrunning manager, with the offering expected to close around July 2, 2025.
